Catalogue

Background
CRF2 is a receptor for corticotropin releasing factor. Shows high-affinity CRF binding. Also binds to urocortin I, II and III. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Expression levels shown to be comparable in adipose tissues and the heart of humans. Expression in adipose tissues suggests a functional role for CRH in human fat.

Synonyms: CRF-R2; CRF2

Source

Immunogen: Synthetic peptide derived from the N-terminal region of the CRF2R protein.

Product

Product Form: Affinity Purified

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Antigen Immunoaffiinity Purification

Concentration: See vial for concentration

Applications
Antibody can be used for Western blotting (1:400 dilution) and immunohistochemistry on paraffin embedded tissues (2-10 µg/ml). Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Western Blotting

Positive Control: Human colorectal tissue

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but our company accepts no liability for any inaccuracies or omissions in this information.

References
1. Liaw, C.W., et al. 'Cloning and characterization of the human corticotropin-releasing factor-2 receptor complementary deoxyribonucleic acid.' Endocrinology 1996, 137, 72-77. 2. Isfort, R.J., et al. 'Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.' J. Med. Chem. 2005, 48, 262-265. 3. Argiles, J.M., et al. 'Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells.' Muscle Nerve 2008, 37, 190-195. 4. Tao, J., et al. 'Activation of corticotropin-releasing factor 2 receptor inhibits Purkinje neuron P-type calcium currents via G(o)alpha-dependent PKC epsilon pathway.' Cell Signal 2009, 21, 1436-1443. 5. Seres, J., et al. 'Corticotropin-releasing hormone system in human adipose tissue.' J. Clin. Endocrin. & Metab. 2004, 89, 965-970.

Protein Reference(s)

Database Name: UniProt

Accession Number: Q13324

Species Accession: Human

Safety Datasheet(s) for this product: